Related Experiment Video

Updated: May 27, 2026

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

Coexistence of PIK3CA and other oncogene mutations in lung adenocarcinoma-rationale for comprehensive mutation

Jamie E Chaft1, Maria E Arcila, Paul K Paik

  • 1Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan-Kettering Cancer Center, Weill Cornell Medical College, New York, New York, USA.

Molecular Cancer Therapeutics
|December 3, 2011
PubMed

Insights

Phosphoinositide-3-kinase catalytic alpha polypeptide (PIK3CA) mutations are found in lung adenocarcinomas, often alongside other driver mutations. Further research is needed to understand their impact on targeted therapy efficacy.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • PIK3CA mutations are linked to cancer development and treatment resistance.
  • The clinical characteristics of PIK3CA-mutant lung adenocarcinomas are not well-defined.

Purpose of the Study:

  • To identify driver mutations in lung adenocarcinoma, focusing on PIK3CA.
  • To describe the clinical features of patients with PIK3CA-mutant lung adenocarcinomas.

Main Methods:

  • Genomic analysis of PIK3CA and other oncogenes (EGFR, KRAS, BRAF, HER2, AKT1, NRAS, MEK1, ALK) in lung adenocarcinoma patients.
  • Retrospective review of clinical data for patients with PIK3CA mutations.

Main Results:

  • PIK3CA mutations were identified in 2% of lung adenocarcinomas, with specific mutations in exon 9 and exon 20.
  • Patients with PIK3CA mutations were typically older, with a significant proportion being never-smokers.
  • Coexisting mutations in KRAS, MEK1, BRAF, ALK, and EGFR were frequent in PIK3CA-mutant tumors.

Conclusions:

  • PIK3CA mutations are present in lung adenocarcinomas and frequently co-occur with other oncogenic mutations.
  • The clinical significance of PIK3CA mutations and their impact on targeted therapies require further investigation.
  • Comprehensive genomic profiling is recommended for patients in clinical trials involving PI3K and other targeted therapies.

Related Concept Videos

Cancer-Critical Genes I: Proto-oncogenes01:33

Cancer-Critical Genes I: Proto-oncogenes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Cancer-Critical Genes I: Proto-oncogenes01:33

Cancer-Critical Genes I: Proto-oncogenes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Cancers Originate from Somatic Mutations in a Single Cell02:21

Cancers Originate from Somatic Mutations in a Single Cell

Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...
Cancer02:18

Cancer

Cancers arise due to mutations in genes involved in the regulation of cell division, which leads to unrestricted cell proliferation. Modern science and medicine have made great strides in the understanding and treatment of cancer, including eradicating cancer in some patients. However, there is still no cure for cancer. This is largely due to the fact that cancer is a large group of many diseases.
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...